Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Pollack

Showing results (241-250 of 265) with videos related to

Pageof 27
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2016
Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical ProstatectomyRahul D Tendulkar, Shree Agrawal, Tianming Gao, et al.
JAMA Oncology|January 27, 2018
Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological FeaturesWilliam L Hwang, Rahul D Tendulkar, Andrzej Niemierko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomyAndrew J Stephenson, Peter T Scardino, Michael W Kattan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 29, 2016
Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancerSkyler Bryce Johnson, Pamela R Soulos, Timothy D Shafman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 19, 2007
Prostate cancer. Clinical practice guidelines in oncologyJames Mohler, Richard J Babaian, Robert R Bahnson, et al.
International Journal of Radiation Oncology, Biology, Physics|January 3, 2023
Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized TrialsPaul L Nguyen, Huei-Chung Rebecca Huang, Daniel E Spratt, et al.
Lancet (London, England)|May 15, 2022
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trialAlan Pollack, Theodore G Karrison, Alexander G Balogh, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|January 20, 2026
MRI-based patient selection for active surveillance in prostate cancer using U-Found: a generalized deep learning modelNoah C Lowry, Adrian L Breto, Veronica Wallaengen, et al.
European Urology Oncology|July 17, 2025
Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 TrialRyan M Phillips, James A Proudfoot, Elai Davicioni, et al.
Urology|August 2, 2008
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancerEdouard J Trabulsi, Richard K Valicenti, Alexandra L Hanlon, et al.
Pageof 27

Showing results (241-250 of 265) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2016
Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical ProstatectomyRahul D Tendulkar, Shree Agrawal, Tianming Gao, et al.
JAMA Oncology|January 27, 2018
Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological FeaturesWilliam L Hwang, Rahul D Tendulkar, Andrzej Niemierko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomyAndrew J Stephenson, Peter T Scardino, Michael W Kattan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 29, 2016
Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancerSkyler Bryce Johnson, Pamela R Soulos, Timothy D Shafman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 19, 2007
Prostate cancer. Clinical practice guidelines in oncologyJames Mohler, Richard J Babaian, Robert R Bahnson, et al.
International Journal of Radiation Oncology, Biology, Physics|January 3, 2023
Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized TrialsPaul L Nguyen, Huei-Chung Rebecca Huang, Daniel E Spratt, et al.
Lancet (London, England)|May 15, 2022
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trialAlan Pollack, Theodore G Karrison, Alexander G Balogh, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|January 20, 2026
MRI-based patient selection for active surveillance in prostate cancer using U-Found: a generalized deep learning modelNoah C Lowry, Adrian L Breto, Veronica Wallaengen, et al.
European Urology Oncology|July 17, 2025
Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 TrialRyan M Phillips, James A Proudfoot, Elai Davicioni, et al.
Urology|August 2, 2008
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancerEdouard J Trabulsi, Richard K Valicenti, Alexandra L Hanlon, et al.
Pageof 27